COVID-19 cases in India increased from 1 lakh to more than 5 lakhs in just 39 days. It is of deep concern, and experts are trying to find a way to control pandemic in the country. The search for an effective drug are continuing, and scientists have identified several promising candidates. Just a couple of weeks ago, researchers at Oxford University have identified a cheap and readily available steroidDexamethasone, and said that he can be effective against heavy COVID-19 cases. It was a major breakthrough in the fight against a new variant of coronavirus, and also recommend you to use this drug in severe cases.
Cheapest drug that can save lives
According to Oxford scientists, the course of treatment to 10 days dexamethasone and costs about £ 5 per patient. So in essence it costs 35 pounds to save a life. They said that steroid can reduce the risk of death by one third for patients on ventilators and a fifth to support oxygen. Now, the Union Ministry of health and family welfare on Saturday released an updated clinical Protocol management COVID-19 cases, advising the use of dexamethasone as an alternative of methylprednisolone for the management of moderate to severe cases. In pace with the development of knowledge about COVID -19, particularly from the point of view of effective drugs, the Ministry released an updated clinical Protocol administration, which had made some changes after reviewing the latest available data and specialist advice.
Widespread steroids that lowers the mortality rate
Dexamethasone is a corticosteroid medication used in a wide range of conditions anti-inflammatory and the impact of immunosuppressant. The drug was tested in patients with COVID -19 in the recovery of clinical research, University of Oxford. Scientists have seen that it is effective in the treatment of critically ill patients. He, obviously, can reduce mortality by approximately one third for patients on a ventilator, and about one-fifth of patients on oxygen therapy. The drug is also included in the national list of essential medicines (NLEM) and widely available. Secretary of the Union of health Preeti Sudan sent an updated Protocol from all States and Union territories to make the necessary arrangements for the availability and use of the updated Protocol and dexamethasone at the institutional level. Last update of clinical management protocols was made on 13 June.
Update on drug use
Dexamethasone is the first drug proven to treat COVID-19. According to the Ministry, for patients with progressive deterioration of oxygenation, the sharp deterioration of the image and excessive activation of the inflammatory response in the body, glucocorticoids can be used for a short period of time (3 to 5 days). According to the recommendations, the dose should not exceed the equivalent Methylprednisolone 1 – 2mg/kg/day or dexamethasone 0.2-0.4 mg/kg/day. A large dose of glucocorticoids will delay the withdrawal syndrome due to immunosuppressive effects.
Prophylactic dose combination NFG or LMWH (e.g., enoxaparin 40 mg / day subcutaneously) may be given to anti-coagulation. Care should be taken to deal with comorbid conditions. For serious complications in pregnant women, consultation with the obstetric, newbornsand intensive care (depending on the condition of the mother) is essential. Patients often suffer from anxiety and fear and they must be supported by psychological counseling.
The Ministry lists the various symptoms COVID-19
According to the updated Protocol, COVID -19 patients reporting to various COVID treatment facilities, reported signs and symptoms as fever, cough, fatigue, shortness of breath, expectoration, myalgia, rhinorrhea, sore throat and diarrhea. Loss of smell (anosmia) or loss of or taste (ageusia), preceding the appearance of symptoms of the respiratory system may also occur. Older people and those with low immunity may be present with atypical symptoms such as fatigue, decreased vigilance, reduced mobility, diarrhoea, loss of appetite, nonsenseand the absence of fever, the Protocol mentions. Children may not have a high temperature or cough as often as adults.
According to the integrated medical information platform (IHIP) or integrated disease surveillance programme (CNRS) portal investigative file forms for COVID -19 at 15,366 people, as well as on 11 June, details on signs and symptoms reported fever (27%), cough (21%), sore throat (10%), dyspnea (8 percent), weakness (7%), rhinitis (3%) and others 24 percent. The main risk factors for severe disease are older than 60 years of age (increases with age), underlying non-communicable diseases (NCDs) such as diabetes, hypertension, heart disease, chronic lung diseaseCerebro-vascular disease, chronic kidney disease, immunosuppression and cancer.
Published : June 28, 2020 11:54 am
to request modification Contact us at Here or [email protected]